Suppr超能文献

相似文献

1
Selective removal of misfolded SOD1 delays disease onset in a mouse model of amyotrophic lateral sclerosis.
Cell Mol Life Sci. 2023 Sep 26;80(10):304. doi: 10.1007/s00018-023-04956-9.
3
ALS-linked SOD1 mutations impair mitochondrial-derived vesicle formation and accelerate aging.
Redox Biol. 2024 Feb;69:102972. doi: 10.1016/j.redox.2023.102972. Epub 2023 Nov 24.
5
Desloratadine alleviates ALS-like pathology in hSOD1 mice via targeting 5HTR on activated spinal astrocytes.
Acta Pharmacol Sin. 2024 May;45(5):926-944. doi: 10.1038/s41401-023-01223-2. Epub 2024 Jan 29.
6
AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS.
Proc Natl Acad Sci U S A. 2019 Jul 16;116(29):14755-14760. doi: 10.1073/pnas.1904665116. Epub 2019 Jul 1.

引用本文的文献

2
Ubiquitination in the Nervous System: From Molecular Mechanisms to Disease Implications.
Mol Neurobiol. 2025 Jul 15. doi: 10.1007/s12035-025-05220-w.
3
From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine.
Int J Mol Sci. 2025 Apr 30;26(9):4271. doi: 10.3390/ijms26094271.
4
Inhibition of SOD1 trimerization is a novel drug target for ALS disease.
Transl Neurodegener. 2025 May 12;14(1):21. doi: 10.1186/s40035-025-00483-8.
5
Landscapes of missense variant impact for human superoxide dismutase 1.
bioRxiv. 2025 Feb 28:2025.02.25.640191. doi: 10.1101/2025.02.25.640191.
6
Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis.
Neurol Sci. 2025 May;46(5):1977-1985. doi: 10.1007/s10072-025-07994-2. Epub 2025 Jan 17.
9
RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice.
bioRxiv. 2024 Jun 25:2024.06.20.599943. doi: 10.1101/2024.06.20.599943.

本文引用的文献

1
Targeted gene silencing in the nervous system with CRISPR-Cas13.
Sci Adv. 2022 Jan 21;8(3):eabk2485. doi: 10.1126/sciadv.abk2485. Epub 2022 Jan 19.
2
Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS.
N Engl J Med. 2020 Jul 9;383(2):151-158. doi: 10.1056/NEJMoa2005056.
3
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS.
N Engl J Med. 2020 Jul 9;383(2):109-119. doi: 10.1056/NEJMoa2003715.
5
Treatment of a Mouse Model of ALS by In Vivo Base Editing.
Mol Ther. 2020 Apr 8;28(4):1177-1189. doi: 10.1016/j.ymthe.2020.01.005. Epub 2020 Jan 14.
6
Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS.
Nat Med. 2020 Jan;26(1):118-130. doi: 10.1038/s41591-019-0674-1. Epub 2019 Dec 23.
8
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models.
J Clin Invest. 2018 Aug 1;128(8):3558-3567. doi: 10.1172/JCI99081. Epub 2018 Jul 16.
9
In vivo genome editing improves motor function and extends survival in a mouse model of ALS.
Sci Adv. 2017 Dec 20;3(12):eaar3952. doi: 10.1126/sciadv.aar3952. eCollection 2017 Dec.
10
Sod1 gene ablation in adult mice leads to physiological changes at the neuromuscular junction similar to changes that occur in old wild-type mice.
Free Radic Biol Med. 2015 Jul;84:254-262. doi: 10.1016/j.freeradbiomed.2015.03.021. Epub 2015 Apr 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验